

## MT2023-01: Safety and Efficacy of Expanded KIR-HLA Mismatched Natural Killer Cell Immunotherapy (AdaptNK) for High-Risk Myeloid Diseases as Bridge to Allogeneic Hematopoietic Stem Cell Transplantation

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- diagnosis of acute myeloid leukemia (AML) - adequate heart, lung, liver, and kidney function - see link to [clinicaltrials.gov](https://clinicaltrials.gov) for complete inclusion criteria

---

**Exclusion Criteria:**

- women who are pregnant or breast feeding - diagnosed with leukemia involving the brain or spinal fluid - active HIV, Hepatitis B, Hepatitis C, other serious infection, recent heart attack, or another active cancer requiring recent chemotherapy - see link to [clinicaltrials.gov](https://clinicaltrials.gov) for complete exclusion criteria

### Conditions & Interventions

**Interventions:**

Biological: AdaptNK, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: IL-2

**Conditions:**

Cancer

**Keywords:**

Clinics and Surgery Center (CSC), acute myeloid leukemia, AML

### More Information

**Description:** The purpose of this study is to evaluate the safety of a new NK cell therapy for people with relapsed or treatment-resistant acute myeloid leukemia (AML). Participants will receive chemotherapy followed by an infusion of specially selected donor immune cells designed to help the body recognize and fight leukemia cells. Researchers will study the safety of this treatment, determine the most appropriate dose, and learn more about how the therapy works in the body.

**Study Contact:** Alycia Lape-Krawczynski - [lape0021@umn.edu](mailto:lape0021@umn.edu)

**Principal Investigator:** Mark Juckett

**Phase:** PHASE1

**IRB Number:** STUDY00027586

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.